Document is current

Article History

Received: 20 May 2024

Accepted: 7 October 2024

First Online: 12 November 2024

Declarations

:

: This study was approved by the institutional ethics committee (no. 8172-BO-K-2018).

: Not applicable.

: The authors declare no conflict of interest. Outside the submitted work, the authors received honoraria for lectures, travel grants, or research grants. KFJ received research support from Else Kröner Fresenius Foundation and travel compensation and congress fee from Merck and Novartis. TT received honoraria from Boehringer Ingelheim, Janssen and Galapagos. LML reports no disclosures. FFK received travel grants from Merck and Novartis. AH reports no disclosures. LH reports no disclosures. YEG reports no disclosures. PS reports no disclosures. KWS reports honoraria for lectures or travel reimbursements for attending meetings from Biogen, Merck, Bavarian Nordic and Bristol-Myers Squibb as well as research support from Bristol-Myers Squibb. JS received lecture fees from Merck and Sanofi, and travel grant from Novartis and Sanofi. MPW received speaker or consultancy honoraria from Alexion, Bayer Healthcare, Biogen, Biologix, Bristol Myers Squibb, Celgene, Genilac, Imcyse, IXICO, Icometrix, Medison, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and publication royalties from Springer and Elsevier. TW reports honoraria for lectures and travel grants from Abbvie, Biogen, Boehringer Ingelheim, Celgene, Chugai, CSL Behring, Euroimmun, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Siemens, Takeda, UCB. CK received lecture and consultancy fees from Biogen, Roche, and Novartis. RP received honoraria for lecturing and consulting from Alexion, Bayer Healthcare, Biogen, Bristol-Mayers Squibb, Hexal, Merck Serono, Mylan, Novartis, Roche, Sanofi Genzyme. He received research funds from Merck Serono and Novartis. HT has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Diamed, Fresenius, Fujirebio, GlaxoSmithKline, Horizon, Janssen-Cilag, Merck, Novartis, Roche, Sanofi-Genzyme, Siemens, and Teva. All not related to the present work. SG received consulting and/or speaker honoraria from Alexion, Alnylam Pharmaceuticals, AstraZeneca, GSK, Pfizer and Merck. His research is supported by the Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Hannover Biomedical Research School (HBRS), Alnylam Pharmaceuticals and CSL Behring. TS reports research support from Alnylam Pharmaceuticals, CSL Behring, Novartis, Siemens; honoraria for lectures and travel expenses for attending meetings from Alexion, Alnylam Pharmaceuticals, argenx, Bayer Vital, Biogen, Bristol Myers Squibb, Celgene, Centogene, CSL Behring, Euroimmun, Grifols, Hexal AG, Horizon, Janssen-Cilag, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens, Swedish Orphan Biovitrum, Teva, Viatris; consultant fees from Alexion, Alnylam Pharmaceuticals, Biogen, Centogene, CSL Behring, Grifols, Hexal AG, Janssen-Cilag, Merck Serono, Novartis, Roche, Sanofi, Swedish Orphan Biovitrum, Viatris.